Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Journal of Clinical & Experimental OncologyISSN: 2324-9110
Pfirrmann RW Author
Subjects of specialization
Affiliation
Colorectal cancer, Cancer chemotherapy, Prostate biomarker, Endometrial cancer
Geistlich Pharma AG, Wolhusen, Switzerland
Biography
Pfirrmann RW was working in the Geistlich Pharma AG, Wolhusen, Switzerland. He has more than 40 publications. His current research area related to osteoarthropathy. He was specialised in oncology.
Publications
Research Article Open Access
Single Versus Double Ring Structure: Search for Best Anti-Neoplastic Driver in Colon and Pancreatic Cancer Cells-Taurultam or Taurolidine?
Author(s): Buchholz M*, Berg J, Braumann C, Majchrzak-Stiller B, Hahn S, Pfirrmann RW, UhI W and Chromik AM
Background: Since the molecular mechanism of the well-known anti-infective and antineoplastic substance Taurolidine (TRD) is still unknown, we sought to analyze the anti-neoplastic capacity of its main metabolite Taurultam (TAU) in malignant human cell lines derived from pancreatic cancer (AsPC-1, BxPC-3, HPAF II, MiaPaca-2, Panc-1) and colon cancer (SW-480, HT-29 and HCT-116) in vitro.
Methods: Cell lines were incubated with TAU or TRD in increasing concentrations for 24h and 48h. Comprehensive analyses were performed to quantify the anti-neoplastic activity of TAU: Analysis of cytotoxicity via MTT-assay, inhibition of proliferation via BrdU and induction of apoptosis and necrosis via FACS-analysis. Furthermore, cell growth was monitored usin... view more»
Google Scholars / Researchers Sites
